Higher HDL Cholesterol Levels Are Associated with Increased Markers of Interstitial Myocardial Fibrosis: Insights from The Multi-Ethnic Study of Atherosclerosis

Abstract Background: Emerging research indicates that high HDL-C levels might not be cardioprotective, potentially worsening cardiovascular disease(CVD)outcomes. Yet, there's no data on HDL-C's association with other CVD risk factors like myocardial fibrosis, a key aspect of cardiac remodeling predicting negative outcomes. We therefore aimed to study the association between HDL-C levels with interstitial myocardial fibrosis (IMF) and myocardial scar measured by CMR T1-mapping and late-gadolinium enhancement(LGE), respectively. Methods: There were 1,863 participants (mean age of 69-years) who had both serum HDL-C measurements and underwent CMR. Analysis was done among those with available indices of interstitial fibrosis (extracellular volume fraction[ECV];N=1,172 and native-T1;N=1,863) and replacement fibrosis by LGE(N=1,172). HDL-C was analyzed as both logarithmically-transformed and categorized into<40(low),40-59(normal),and≥60mg/dL(high). Multivariable linear and logistic regression models were constructed to assess the associations of HDL-C with CMR-obtained measures of IMF, ECV% and native-T1 time, and myocardial scar, respectively. Results: In the fully adjusted model, each 1-SD increment of log HDL-C was associated with a 1% increment in ECV%( p =0.01) and an 18-ms increment in native-T1( p <0.001). When stratified by HDL-C categories, those with high HDL-C(≥60mg/dL) had significantly higher ECV(β=0.5%, p =0.01) and native-T1(β=7ms, p =0.01) compared with those with normal HDL-C levels. Those with low HDL-C were not associated with IMF. Results remained unchanged after excluding individuals with a history of myocardial infarction. Neither increasing levels of HDL-C nor any HDL-C category was associated with the prevalence of myocardial scar. Conclusions: Increasing levels of HDL-C were associated with increased markers of IMF, with those with high levels of HDL-C being linked to subclinical fibrosis in a community-based setting.

[1]  A. von Eckardstein,et al.  High-density lipoprotein revisited: biological functions and clinical relevance , 2022, European heart journal.

[2]  Marc P. Bonaca,et al.  Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment–Elevation Myocardial Infarction: Results of REAL-TIMI 63B , 2022, Circulation.

[3]  P. Munroe,et al.  Incident Clinical and Mortality Associations of Myocardial Native T1 in the UK Biobank , 2022, JACC. Cardiovascular imaging.

[4]  I. Fernández-Ruíz Very high HDL-C levels are associated with higher mortality in patients with CAD , 2022, Nature Reviews Cardiology.

[5]  O. Kepp,et al.  Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity , 2022, Circulation.

[6]  Yan V. Sun,et al.  Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. , 2022, JAMA cardiology.

[7]  G. Fonarow,et al.  Very Elevated High-Density Lipoprotein Cholesterol and Mortality-The Good Gone Bad? , 2022, JAMA cardiology.

[8]  R. Vasan,et al.  Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program , 2022, Communications biology.

[9]  Annabelle Rodriguez High HDL-Cholesterol Paradox: SCARB1-LAG3-HDL Axis , 2021, Current Atherosclerosis Reports.

[10]  M. Salerno,et al.  Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations. , 2019, JACC. Cardiovascular imaging.

[11]  Richard B. Thompson,et al.  The Effect of Blood Composition on T1 Mapping. , 2019, JACC. Cardiovascular imaging.

[12]  R. Amin,et al.  Hepatocyte-Specific SR-BI Gene Transfer Corrects Cardiac Dysfunction in Scarb1-Deficient Mice and Improves Pressure Overload-Induced Cardiomyopathy , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[13]  B. Nordestgaard,et al.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies. , 2017, Atherosclerosis.

[14]  K. Taylor,et al.  Lymphocyte activation gene 3 and coronary artery disease. , 2016, JCI insight.

[15]  R. Henriksson,et al.  Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice. , 2016, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  M. Budoff,et al.  Prevalence and Correlates of Myocardial Scar in a US Cohort. , 2015, JAMA.

[17]  H. Kaur,et al.  Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression , 2014, PloS one.

[18]  Chia-Ying Liu,et al.  Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). , 2013, Journal of the American College of Cardiology.

[19]  A. Akhmedov,et al.  Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. , 2013, Immunity.

[20]  P. Kellman,et al.  Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality , 2012, Circulation.

[21]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[22]  R. Kronmal,et al.  Multi-Ethnic Study of Atherosclerosis: objectives and design. , 2002, American journal of epidemiology.

[23]  D. White Paramagnetic iron (III) MRI contrast agents , 1991, Magnetic resonance in medicine.

[24]  E. Nagel,et al.  T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure. , 2016, JACC. Cardiovascular imaging.

[25]  P. P. Toth Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy , 2012 .